Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

Abstract:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

Pasadena. CA | Posted on December 2nd, 2020

Piper Sandler 32nd Annual Virtual Healthcare Conference – December 1-3, 2020

December 2, 2020 – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation. Recording is available on demand

20th Gordon L. Snider Critical Issues Workshop – The Promise of Gene-based Interventions in Alpha-1 Antitrypsin Deficiency – December 12, 2020

December 12, 2020, 12:55 p.m. EST – James Hamilton, M.D., MBA, Arrowhead’s senior vice president of discovery and translational medicine, will deliver an oral presentation titled, “Arrowhead’s approach to gene silencing - ARO-AAT for liver disease in Alpha-1 antitrypsin deficiency”

A copy of the presentation materials and/or webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Wearable sensors that detect gas leaks April 19th, 2021

JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021

FSU engineers improve performance of high-temperature superconductor wires April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

French & Swiss Scientists Demonstrate ‘All-in-One’ Technique that Could Accelerate Phage-Therapy Diagnosis: Lensless Imaging System Affirms Phage Therapy’s Value in Treating Serious Infection, Tracks Phage Resistance and Could Easily Be Implemented in Compact Devices at Phage Lab April 13th, 2021

Antibody binding-site conserved across COVID-19 virus variants: The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants April 9th, 2021

Announcements

Wearable sensors that detect gas leaks April 19th, 2021

JEOL USA Welcomes New Managing Director, Hidetaka Sawada April 19th, 2021

FSU engineers improve performance of high-temperature superconductor wires April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

CEA-Leti Envisions Widespread Use of LiDAR Systems Based on Integrated Optical Phased Arrays (OPAs): OPAs with Solid-State Beam Steering Can Reduce the Cost and Size of LiDAR Systems & Improve Performance; Results Reported at Photonics West 2021 March 9th, 2021

CEA-Leti Announces 16 Papers to Be Presented At Photonics West 2021 and a Virtual Workshop on March 25 March 3rd, 2021

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

French & Swiss Scientists Demonstrate ‘All-in-One’ Technique that Could Accelerate Phage-Therapy Diagnosis: Lensless Imaging System Affirms Phage Therapy’s Value in Treating Serious Infection, Tracks Phage Resistance and Could Easily Be Implemented in Compact Devices at Phage Lab April 13th, 2021

Energy transmission by gold nanoparticles coupled to DNA structures April 9th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project